News Column

Investigators at University of California Discuss Findings in Immunotherapy (p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD...

August 18, 2014



Investigators at University of California Discuss Findings in Immunotherapy (p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss new findings in Biotechnology. According to news originating from Irvine, California, by NewsRx correspondents, research stated, "Alzheimer's disease (AD) is a proteinopathy characterized by the accumulation of beta-amyloid (A beta) and tau. To date, clinical trials indicate that A beta immunotherapy does not improve cognition."

Our news journalists obtained a quote from the research from the University of California, "Consequently, it is critical to modulate other aspects of AD pathology. As such, tau represents an excellent target, as its accumulation better correlates with cognitive impairment. To determine the effectiveness of targeting pathological tau, with A beta pathology present, we administered a single injection of AT8, or control antibody, into the hippocampus of aged 3xTg-AD mice. Extensive data indicates that phosphorylated Ser(202) and Thr(205) sites of tau (corresponding to the AT8 epitope) represent a pathologically relevant target for AD. We report that immunization with AT8 reduced somatodendritic tau load, p-tau immunoreactivity, and silver stained positive neurons, without affecting A beta pathology. We also discovered that tau pathology soon reemerges post-injection, possibly due to persistent A beta pathology."

According to the news editors, the research concluded: "These studies provide evidence that targeting p-tau may represent an effective treatment strategy: potentially in conjunction with A beta immunotherapy."

For more information on this research see: p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neuroscience Letters, 2014;575():96-100. Neuroscience Letters can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Neuroscience Letters - www.elsevier.com/wps/product/cws_home/506081)

The news correspondents report that additional information may be obtained from K.C. Walls, University of California, Inst Memory Impairments & Neurol Disorders, Irvine, CA 92697, United States. Additional authors for this research include R.R. Ager, V. Vasilevko, D. Cheng, R. Medeiros and F.M. LaFerla (see also Biotechnology).

Keywords for this news article include: Biotechnology, Irvine, Pathology, California, United States, Immunotherapy, Immunomodulation, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters